Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 24.3%

BriaCell Therapeutics Corp. (NASDAQ:BCTXGet Rating) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 1,870,000 shares, a decrease of 24.3% from the April 15th total of 2,470,000 shares. Based on an average daily volume of 837,600 shares, the days-to-cover ratio is presently 2.2 days. Currently, 15.7% of the shares of the company are sold short.

Separately, HC Wainwright started coverage on shares of BriaCell Therapeutics in a research report on Monday, February 14th. They issued a “buy” rating and a $25.00 price target on the stock.

A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in shares of BriaCell Therapeutics in the 2nd quarter valued at $59,000. Morgan Stanley bought a new stake in BriaCell Therapeutics in the second quarter valued at about $97,000. Bank of America Corp DE acquired a new position in BriaCell Therapeutics in the second quarter worth about $119,000. Geode Capital Management LLC bought a new position in BriaCell Therapeutics during the third quarter worth about $326,000. Finally, Voloridge Investment Management LLC acquired a new stake in BriaCell Therapeutics during the third quarter valued at approximately $1,271,000. 16.86% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BCTX opened at $4.94 on Monday. The stock’s 50-day moving average price is $8.19 and its 200 day moving average price is $8.32. BriaCell Therapeutics has a 12-month low of $2.82 and a 12-month high of $12.47.

BriaCell Therapeutics (NASDAQ:BCTXGet Rating) last released its quarterly earnings data on Tuesday, March 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). Analysts anticipate that BriaCell Therapeutics will post -0.77 EPS for the current fiscal year.

BriaCell Therapeutics Company Profile (Get Rating)

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

Featured Articles

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with's FREE daily email newsletter.